After Hiccups, Astellas’s Mirabegron On Course For Indian Debut?
Executive Summary
Astellas’s overactive bladder drug mirabegron, which previously failed to pass muster in India, has now been cleared by an expert panel in the country, though competition appears to be building up alongside.
You may also be interested in...
More M&A For Astellas As It Pursues New Mid-Term Goals?
Astellas's new mid-term business plan envisages mid-single-digit sales growth for the company over the next two years, with new products in oncology and urology the main drivers of the expected increase and further acquisitions seemingly on the cards. The firm has also just set up a new U.S. joint venture to pursue R&D in new therapeutic areas.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet